Source link : https://www.newshealth.biz/health-news/fda-approves-osimertinib-for-unresectable-nsclc/
The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment of locally advanced, unresectable non–small cell lung cancer (NSCLC) in certain adult patients. Specifically, the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) was approved for patients whose disease has not progressed during or after concurrent or […]
Author : News Health
Publish date : 2024-09-27 05:09:55
Copyright for syndicated content belongs to the linked Source.
Categories